Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90d41c5c08b4cc27008c8d448154a71f |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6843 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2016-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5b9dde400ed5a5907a02b79438e9f51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bda2dcc178cd7596d0530015ff2e11ef |
publicationDate |
2021-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3919081-A1 |
titleOfInvention |
Dosing regimens for anti-tf-antibody drug-conjugates |
abstract |
Anti-TF antibody drug conjugate and pharmaceutical compositions comprising the antibody drugconjugate for use in the treatment of a solid cancer comprising administering to a subject a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an anti-TF antibody drug conjugate once a week for three consecutive weeks followed by a one week resting period without any administration of anti-TF ADC so that each cycle time is 28 days including the resting period. |
priorityDate |
2015-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |